Factors increasing survival of patients with cervical cancer in the Kyrgyz Republic

View or download the full article: 
PDF icon health-risk-analysis-2025-4-16.pdf
UDC: 
614.2:616-006
DOI: 
10.21668/health.risk/2025.4.16.eng
Authors: 

D.D. Ibraimova1, A.D. Ibraimova2, M.A. Mambetov1, A.E. Samigullina3

Organization: 

1Kyrgyz-Russian Slavic University named after B.N. Yeltsin, 44 Kievskaya Str., Bishkek, 720000, Kyrgyz Republic
2Kyrgyz State Medical Academy named after I.K. Akhunbaev, 92 Akhunbaeva Str., Bishkek, 720020, Kyrgyz Republic
3Bishkek International Medical Institute, 4a Shabdan Baatyr Ave., Bishkek, 720064, Kyrgyz Republic

Abstract: 

According to the International Agency for Research on Cancer, cervical cancer holds the 2nd rank place among oncological diseases of the female reproductive system. In the Kyrgyz Republic, primary incidence of malignant neoplasms of the cervix has been established to be high with an ascending trend identified in 2021. Mortality from cervical cancer in general falls on the most able-bodied age from 45 to 59 years. Therefore, there are significant reserves for reducing mortality from malignant neoplasms, which is important in organizing cancer care and planning targeted prevention programs.
A regional analysis of the dynamics of 5-year survival of patients with cervical cancer in the Kyrgyz Republic was carried out according to statistics from the National Center for Oncology and Hematology of the Ministry of Health of the Kyrgyz Republic for the period 2016–2024.

The analysis results revealed that in the Kyrgyz Republic as a whole, survival remained relatively stable, ranging from 38.7 to 36.9 %, with a peak in 2021. In all years of follow-up, the survival rate in patients with cervical cancer exceeded the average rates by 2–6 %, which indicates more favorable outcomes of this disease with timely detection and complex treatment.

The highest survival rates were recorded in the Naryn region; the lowest, in the Jalal-Abad, Osh and Issyk-Kul regions of the republic. At the same time, in 2022–2024, there was a decrease in average survival rate to 35.5 %.

In the Kyrgyz Republic as a whole, the Family Medicine Centers have 67.25 positions of oncologists, of which 58.0 are occupied and 9.25 are vacant; 36 of employed doctors are true oncologists. In total, there are 572 cancer beds in the republic. With the population of 7,281,800 as of January 1, 2025, the provision of cancer beds is 0.7 per 10,000 people.

The lack of oncologists at the primary level and low provision of beds leads to late diagnosis and a decrease in effectiveness of treatment. Expansion of prevention is an additional factor in improving prognosis in cervical cancer, including increased human papillomavirus vaccination coverage. In the Kyrgyz Republic, vaccination against the human papillomavirus has been introduced in girls aged 11 since 2022, but in the same year girls aged 12–14 years were also vaccinated. In the republic, there is an increase in vaccination coverage to 70.4 % in the I-III quarters of 2025.

Strengthening human resources and implementing prevention programs are considered key factors in improving survival in cervical malignancies.

Keywords: 
human papillomavirus, survival, malignancies, public health, oncologist, cancer morbidity, prevention, cancer, mortality, cervix
Ibraimova D.D., Ibraimova A.D., Mambetov M.A., Samigullina A.E. Factors increasing survival of patients with cervical cancer in the Kyrgyz Republic. Health Risk Analysis, 2025, no. 4, pp. 165–172. DOI: 10.21668/health.risk/2025.4.16.eng
References: 
  1. Klinyshkova T.V., Turchaninov D.V., Buyan M.S. Epidemiological aspects of cervical cancer. Rossiiskii vestnik akushera-ginekologa, 2018, vol. 18, no. 2, pp. 22–26 (in Russian).
  2. Efimova N.V., Myl'nikova I.V. Assessment of the contribution made by oncogenic factors to the risk of malignant neoplasms development for the urban population of working age. Health Risk Analysis, 2021, no. 3, pp. 99–107. DOI: 10.21668/health.risk/2021.3.09.eng
  3. Efimova N.V., Rukavishnikov V.S., Myl’nikova I.V. Comprehensive epidemiological analysis of the risk of malignant neoplasms: experience of the implementation. Gigiena i sanitariya, 2021, vol. 100, no. 11, pp. 1317–1322. DOI: 10.47470/0016-9900-2021-100-11-1317-1322 (in Russian).
  4. Kulieva G.Z., Mkrtchyan L.S., Krikunova L.I., Ivanov S.A., Kaprin A.D. Epidemiological aspects of the incidence and mortality of cervical cancer (literature review). Opukholi zhenskoi re-produktivnoi sistemy, 2023, vol. 19, no. 3, pp. 77–84. DOI: 10.17650/1994-4098-2023-19-3-77-84 (in Russian).
  5. Zhang S., Xu H., Zhang L., Qiao Y. Cervical cancer: epidemiology, risk factors and screening. Chin. J. Cancer Res., 2020, vol. 32, no. 6, рр. 720–728. DOI: 10.21147/j.issn.1000-9604.2020.06.05
  6. Gopu P., Antony F., Cyriac S., Karakasis K., Oza A.M. Updates on systemic therapy for cervical cancer. Ind. J. Med. Res., 2021, vol. 154, no. 2, рр. 293–302. DOI: 10.4103/ijmr.IJMR_4454_20
  7. Choi S., Ismail A., Pappas-Gogos G., Boussios S. HPV and cervical cancer: a review of epidemiology and screening uptake in the UK. Pathogens, 2023, vol. 12, no. 2, pp. 298. DOI: 10.3390/pathogens12020298
  8. Nygard M., Nygard S. The future of cervical cancer prevention: from "one-size-fits-all" to personalized screening. J. Pers. Med., 2023, vol. 13, no. 2, pp. 161. DOI: 10.3390/jpm13020161
  9. Tilekov E.A., Ibraimova D.D., Bolbachan O.A., Ishenova G.I., Nasirova N.M. Primary incidence of cervical cancer by regions of the Kyrgyz Republic. Vestnik KGMA, 2022, vol. 5, no. 5, рр. 40–48 (in Russian).
  10. Bukuev N.M., Sultangazieva B.B., Makimbetov E.K., Toktonalieva A., Yusufova M.A. Trends of cervical cancer incidence in the Kyrgyz Republic. Mezhdunarodnyi zhurnal gumanitarnykh i estestvennykh nauk, 2021, vol. 4–2, no. 55, pp. 135–138. DOI: 10.24412/2500-1000-2021-4-2-135-138 (in Russian).
  11. Ibraimova D.D., Tilekov E.A., Shaimbetov В.O., Bekeshova E.N. The lost years of poten-tial life under cancer of neck of uterus in the Kyrgyz Republic. Problemy sotsial'noi gigieny, zdra-vookhraneniya i istorii meditsiny, 2024, vol. 32, no. 3, pp. 462–466. DOI: 10.32687/0869-866X-2024-32-3-462-466 (in Russian).
  12. Arbyn M., Weiderpass E., Bruni L., de Sanjosé S., Saraiya M., Ferlay J., Bray F. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health, 2020, vol. 8, no. 2, pp. e191–e203. DOI: 10.1016/S2214-109X(19)30482-6
  13. Ormonova Zh.A. Genetic predisposition to cervical cancer. Nauchnoe obozrenie. Med-itsinskie nauki, 2022, no. 2, pp. 37–41. DOI: 10.17513/srms.1238 (in Russian).
  14. Knyshova L.P. Zlokachestvennye novoobrazovaniya kak mediko-sotsial'naya problema [Malignant neoplasms as a medical and social problem]. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii, 2016, no. 5–4, pp. 671–672 (in Russian).
  15. Merabishvili V.M., Belyaev A.M. The state of oncology care in Russia: dynamics of five-year survival of patients with malignant neoplasms and its ranked distribution across all tumor sites. Population study at the level of the Northwestern Federal District of Russia. Voprosy onko-logii, 2023, vol. 69, no. 2, pp. 227–237. DOI: 10.37469/0507-37582023-69-2-227-237 (in Russian).
  16. Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Nikšić M., Bonaventure A., Valkov M. [et al.]. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet, 2018, vol. 391, no. 10125, pp. 1023–1075. DOI: 10.1016/S0140-6736(17)33326-3
  17. Sengayi-Muchengeti M., Joko-Fru W.Y., Miranda-Filho A., Egue M., Akele-Akpo M.-T., N'da G., Mathewos A., Buziba N. [et al.]. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int. J. Cancer, 2020, vol. 147, no. 11, pp. 3037–3048. DOI: 10.1002/ijc.33120
  18. Rudd P., Gorman D., Meja S., Mtonga P., Jere Y., Chidothe I., Msusa A.T., Bates M.J. [et al.]. Cervical cancer in southern Malawi: A prospective analysis of presentation, management, and outcomes. Malawi Med. J., 2017, vol. 29, no. 2, pp. 124–129. DOI: 10.4314/mmj.v29i2.9
  19. Grigsby P.W., Massad L.S., Mutch D.G., Powell M.A., Thaker P.H., McCourt C., Hagemann A., Fuh K. [et al.]. FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecol. Oncol., 2020, vol. 157, no. 3, pp. 639–643. DOI: 10.1016/j.ygyno.2020.03.027
  20. Ormonova Zh.A., Makieva K.B., Makimbetov E.K., Toktanalieva A.N., Azhimamatova Zh.T. Rak sheiki matki v mire (tendentsii, faktory riska) [Cervical cancer worldwide (trends, risk factors)]. Nauchnoe obozrenie. Meditsinskie nauki, 2023, no. 4, pp. 35–40. DOI: 10.17513/srms.1352 (in Russian).
  21. Mamedova L.T. Cervical cancer: factors of prognosis and follow-up results. Vestnik RONTs im. N.N. Blokhina RAMN, 2002, pp. 47–51.
Received: 
15.11.2025
Approved: 
11.12.2025
Accepted for publication: 
26.12.2025

You are here

Home